Catalog No.
YHB86202
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Val2144-Tyr2351
Predicted molecular weight
26 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P00451
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Coagulation factor VIII, Antihemophilic factor, AHF, Procoagulant component, Factor VIIIa heavy chain, 200 kDa isoform, Factor VIIIa heavy chain, 92 kDa isoform, Factor VIII B chain, Factor VIIIa light chain, F8, F8C
Selected cell receptor genotypes differentially modulate the ABO blood group influence on Factor VIII levels in severe aortic stenosis., PMID:40398046
Cell-Based Small-Molecule Screening Identifying Proteostasis Regulators Enhancing Factor VIII Missense Mutant Secretion., PMID:40305178
Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response., PMID:40300593
Combined deficiency of factor V and factor VIII in a pediatric patient: a case report., PMID:40296097
A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A., PMID:40263602
Rescue of a panel of Hemophilia A-causing 5'ss splicing mutations by unique Exon-specific U1snRNA variants., PMID:40148820
The bleeding edge: broadening horizons for hematopoietic stem cell therapies., PMID:40121135
Comparative Efficacy of Recombinant FVIII and Recombinant FVII Biosimilars in Severe Hemophilia A., PMID:40116719
Hemophilia is associated with accelerated biological aging., PMID:40079104
Discrepancy between one-stage clotting and chromogenic factor VIII activity in women with hemophilia A and hemophilia A carriers: a retrospective clinical study., PMID:40056988
An engineered Treg selective immunocytokine induces sustained immune modulation in a preclinical model of hemophilia A., PMID:40056981
Development of a Single-Tube Reverse Transcription Real-Time PCR Assay for Diagnosis of F8 Intron 22 Inversion in Patients and Carriers of Haemophilia A., PMID:39995019
Enhancing hemophilia A gene therapy by strategic F8 deletions in AAV vectors., PMID:39949501
Noninversion Variants in Sporadic Hemophilia A Originate Mostly from Females., PMID:39940661
A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta® (reference product) in previously treated patients with severe haemophilia A., PMID:39934428
Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature., PMID:39800259
Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study., PMID:39800255
Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab., PMID:39798924
Genomic Landscape of Chromosome X Factor VIII: From Hemophilia A in Males to Risk Variants in Females., PMID:39766791
Investigation of a hemophilia family with one female hemophilia A patient and 12 male hemophilia A patients., PMID:39724248
FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4., PMID:39665218
Genetic Diagnosis and Prenatal Diagnosis of a Rare FVIII Family With Haemophilia A., PMID:39663887
Verification and Implementation of a Bovine Chromogenic Factor VIII Assay for Hemophilia A Patients on Emicizumab Therapy., PMID:39662012
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A., PMID:39655790
Genetic Analysis and Reproductive Interventions for Two Rare Families Affected by Severe Haemophilia A., PMID:39632590
Exploring red blood cells as an antigen delivery system to modulate the immune response towards FVIII in hemophilia A., PMID:39617188
Biophysical characterization of blood coagulation factor VIII binding to lipid nanodiscs that mimic activated platelet surfaces., PMID:39549835
Acquired hemophilia A: a narrative review and management approach in the emicizumab era., PMID:39536818
Comparing one stage, chromogenic assay results and discrepancies with bleeding phenotype and genetic variants in females with hemophilia A., PMID:39536816
Intensive FVIII replacement in hemophilia patients with hypertrophic synovium: a randomized study., PMID:39476971
Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody production., PMID:39476969
[Hemophilia A in a male cat with intermittent lameness]., PMID:39447565
Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation., PMID:39401737
CHIEF: A retrospective self-control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis., PMID:39367598
Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A., PMID:39323385
Clinical validation and application of targeted long-range polymerase chain reaction and long-read sequencing-based analysis for hemophilia: experience from a hemophilia treatment center in China., PMID:39260745
Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk., PMID:39233012
Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors., PMID:39186847
Pathogenic but sweet: factor VIII inhibitor hits the hot spot., PMID:39174227
Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors., PMID:39127324
Mutational Profile in Romanian Patients with Hemophilia A., PMID:39125936
Coagulation factor VIII: biological basis of emerging hemophilia A therapies., PMID:39088776
Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives., PMID:39062568
Detection of hemophilia A genetic variants using third-generation long-read sequencing., PMID:39038592
Acid Treatment of FVIII-Containing Plasma Samples Unmasks a Broad Spectrum of FVIII-Specific Antibodies in ELISA., PMID:39009010
Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL., PMID:38992344
Binding Promiscuity of Therapeutic Factor VIII., PMID:38950594
Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A., PMID:38936699
Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort., PMID:38866249
AAV mediated repression of Neat1 lncRNA combined with F8 gene augmentation mitigates pathological mediators of joint disease in haemophilia., PMID:38864710
For research use only. Not for human or drug use.
